US FDA expands use of Bristol Myers’ cancer therapy (March 14) By Reuters
© Reuters. A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File Photo
(This March 14 story has been corrected to say third approval for treatment, not second approval, in paragraph 1)
(Reuters) – The U.S. Food and Drug Administration on Thursday expanded the use of Bristol Myers (NYSE:) Squibb’s cell therapy, Breyanzi, for a type of slow-growing blood cancer, marking the third approval for the treatment.
